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ARTICLE
The nasal methylome as a biomarker of asthma
and airway inflammation in children
Andres Cardenas 1,2,11, Joanne E. Sordillo2,11, Sheryl L. Rifas-Shiman2, Wonil Chung 3, Liming Liang3,
Brent A. Coull3, Marie-France Hivert2,4, Peggy S. Lai5, Erick Forno6, Juan C. Celedón6, Augusto A. Litonjua 7,
Kasey J. Brennan8, Dawn L. DeMeo9, Andrea A. Baccarelli8, Emily Oken 2 & Diane R. Gold9,10
The nasal cellular epigenome may serve as biomarker of airway disease and environmental
response. Here we collect nasal swabs from the anterior nares of 547 children (mean-age
12.9 y), and measure DNA methylation (DNAm) with the Infinium MethylationEPIC Bead-
Chip. We perform nasal Epigenome-Wide Association analyses (EWAS) of current asthma,
allergen sensitization, allergic rhinitis, fractional exhaled nitric oxide (FeNO) and lung func-
tion. We find multiple differentially methylated CpGs (FDR < 0.05) and Regions (DMRs; ≥
5-CpGs and FDR < 0.05) for asthma (285-CpGs), FeNO (8,372-CpGs; 191-DMRs), total IgE
(3-CpGs; 3-DMRs), environment IgE (17-CpGs; 4-DMRs), allergic asthma (1,235-CpGs;
7-DMRs) and bronchodilator response (130-CpGs). Discovered DMRs annotated to genes
implicated in allergic asthma, Th2 activation and eosinophilia (EPX, IL4, IL13) and genes
previously associated with asthma and IgE in EWAS of blood (ACOT7, SLC25A25). Asthma,
IgE and FeNO were associated with nasal epigenetic age acceleration. The nasal epigenome is
a sensitive biomarker of asthma, allergy and airway inflammation.
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Asthma, a chronic respiratory disease characterized byreversible airflow obstruction and airway inflammation,affects over 300 million people worldwide1. While genetic
factors are thought to account for approximately 60% of asthma
susceptibility2, the remaining proportion is believed to result
from environmental exposures. The epigenome is at the inter-
section of these two broad classes of causal factors: genes and
environment, providing a unique opportunity to understand the
interplay between genetic and environmental factors.
DNA methylation (DNAm) of cytosine nucleotides (CpG sites)
is one of the most widely studied epigenetic modifications3.
DNAm has been shown to be a promising biomarker of diseases4
and immune phenotypes, including asthma5,6, allergy7, and
immunoglobulin E (IgE) levels8,9. However, most studies have
been performed in whole blood DNA. DNAm is tissue specific,
and collection of target tissue is critical for the development of
disease-relevant biomarkers. The upper respiratory tract is in
direct contact with the external environment and respiratory
epithelial cells provide multiple barrier functions, including the
capability to directly signal immune cells for protection and
clearance of microbial pathogens, particles, and toxicants10,11.
Epithelial barrier abnormalities and unbalanced immune system
activation can lead to airway disease. Previous studies have sug-
gested the relevance of nasal cells as epigenetic biomarkers of
lower airway disease and asthma12,13.
In epigenome-wide association analyses (EWAS) of nasal
samples collected from 547 early-teen children, we hypothesized
that the DNAm signatures would serve as biomarkers of airway
disease, airway inflammation, allergen sensitization, and lung
function. We theorized that these signatures would reflect epi-
genetic modifications of T-helper type 2 (Th2) immune signaling
and epithelial barrier genes, which are known to play a role in
allergy and asthma14. In addition, we hypothesized that asthma,
allergy, IgE, and lung function would be associated with accel-
erated epigenetic aging of nasal cells. We show that allergic
asthma and elevated biomarkers of allergic disease, such as
fractional exhaled nitric oxide (FeNO) and IgE, are associated
with multiple differentially methylated CpGs and regions of genes
that may alter the structure and function of epithelial cells and
genes implicated in allergic asthma, Th2 activation, and eosino-
philia. No associations between nasal DNAm and lung function
or allergic rhinitis was observed. Finally, asthma and elevated
markers of allergic disease are associated with accelerated epige-
netic aging in nasal cells.
Results
Study characteristics. We collected nasal DNA samples year
round: 33.6% in summer, 21.9% in fall, 19% in winter, and 25.4%
in spring. We measured nasal DNAm among N= 547 Project
Viva participants at the early teen visit with a mean age 12.9 years
(SD= 0.65), range 11.9–15.3 years. Participants were 50.6% male,
and 67.1% white, 16.1% black, 4.2% Hispanic, 3.1% Asian, and
9.3% of more than one race. Overall, 12% reported current
asthma and 16.7% reported symptoms consistent with current
allergic rhinitis. Of the 366 participants with IgE sensitization
testing, 58.7% were sensitized to environmental allergens
(Table 1).
Global DNAm variability. Univariate associations of principal
components (PCs) from the nasal DNAm data (PCs 1–30 on the
x-axis) with covariates and surrogates of cell-type mixture (PCs
1–10 from ReFACTor on y-axis) are shown in Fig. 1. Overall, the
first 30 PCs, derived from 719,075 high-quality CpGs, explained
59% of the variance of the nasal methylome. As expected, cell-
type PCs estimated via ReFACTor (a reference-free method)
showed the strongest associations with top nasal DNAm PCs. Sex,
race, age at nasal sample collection, and season were associated
with the first nasal DNAm PC. FeNO and total IgE were asso-
ciated with the second PC suggesting strong associations with
these phenotypes.
CpG-by-CpG and regional DNAm analyses. In linear models
adjusted for child race/ethnicity, sex, age at nasal sample collec-
tion, body mass index (BMI) z-score, maternal education, smo-
kers living in the household, sine and cosine of season at sample
Table 1 Study characteristics of Project Viva participantsa
Characteristics N (%) or mean (SD)
Sex
Male 277 (50.6%)
Female 270 (49.4%)
Race/ethnicity
White 367 (67.1%)
Black 88 (16.1%)
Hispanic 23 (4.2%)
Asian 17 (3.1%)
More than one race 51 (9.3%)
Missing 1
Mother’s education
College graduate 379 (69.5%)
No college education 166 (30.5%)
Missing 2
Child age (years) 12.9 (0.65)
BMI z-score 0.41 (1.07)
Missing 1
Smokers living at home
Yes 67 (12.4%)
No 474 (87.6%)
Missing 6
Season at sample collection
Summer 184 (33.6%)
Fall 120 (21.9%)
Winter 104 (19.0%)
Spring 139 (25.4%)
Asthma
Current 65 (12.0%)
Past but not current 74 (13.7%)
Never 402 (73.5%)
Missing 6
Allergic rhinitis
Current 47 (16.7%)
Never 234 (83.3%)
Missing 266
Environment IgE sensitization
Yes 215 (58.7%)
No 151 (41.3%)
Missing 181
Total IgE (kU L−1) 189.3 (368.7)
Missing 181
FeNO (ppb) 27.7 (29.5)
Missing 21
FEV z-score −0.15 (1.05)
Missing 14
FVC z-score 0.07 (1.00)
Missing 14
FEV1/FVC z-score −0.38 (0.99)
Missing 181
BDR 3.4% (6.8)
Missing 85
BMI body mass index, IgE immunoglobulin E, FeNO fractional exhaled nitric oxide, BDR
bronchodilator response, FEV forced expiratory volume, FVC forced vital capacity
aDuring the early-teen visit among participants with complete nasal DNA methylation data after
quality control (N = 547)
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collection, and cell-type heterogeneity, we observed multiple
differentially methylated CpGs (false discovery rate (FDR) < 0.05)
and regions (DMRs; ≥5-CpGs and FDR < 0.05) for current
asthma (285 CpGs), FeNO (8372 CpGs; 191 DMRs), total IgE (3
CpGs; 3 DMRs), environmental allergen IgE sensitization (17
CpGs; 4 DMRs), allergic asthma with IgE sensitization (1235
CpGs; 7 DMRs), and bronchodilator response (BDR) (130 CpGs).
Allergic rhinitis and lung function measures (forced expiratory
volume (FEV), forced vital capacity (FVC), FEV/FVC ratio) were
not associated with differential DNAm of nasal cells in adjusted
models (Table 2). Genomic inflation observed in EWAS not
adjusted for cell-type heterogeneity was greatly attenuated after
adjustment for surrogates of cell types estimated via ReFACTor
(Supplementary Figure 1). Manhattan plots of fully adjusted
EWAS of (a) FeNO, (b) current asthma, and (c) allergic asthma
are shown in Fig. 2.
Biological pathway analyses using the Kyoto Encyclopedia of
Genes and Genomes (KEGG) showed that the asthma pathway
was differentially methylated among significant genes in EWAS of
allergic asthma and FeNO. In addition, the interleukin-17 (IL-17)
signaling pathway was differentially methylated for FeNO
(Supplementary Table 1).
Overlap across phenotypes. By far, the largest number of dif-
ferentially methylated sites and DMRs were associated with
FeNO levels. The majority of differentially methylated CpGs
(FDR < 0.05) associated with current asthma, total IgE, positive
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Fig. 1 Associations with Global Nasal DNA methylation (DNAm) variability. Principal component (PC) regression analysis showing univariate association
P values color-coded by smallest P value (dark red; P < 10−10) to largest (blank; P > 0.10) between all covariates of interest and the top 30 PCs explaining
59% of the variance of the nasal DNA methylation data in the x-axis. PCs 1–10 on the y-axis reflect DNAm heterogeneity and differences in cell types
bioinformatically estimated using ReFACTor
Table 2 Summary of nasal EWASa
EWASb Sample size (N; n= cases) Fully adjusted EWAS
λ FDR < 0.05 CpGs Bonferroni CpGs DMRs
Current asthma vs. never N= 463; n= 65 0.91 285 1 0
FeNO N= 517 1.32 8372 744 191
Current allergic rhinitis vs. never N= 277; n= 47 1.08 0 0 0
Total IgE N= 361 1.09 3 1 3
Environment IgE sensitization N= 361; n= 211 0.93 17 6 4
Current asthma with environment IgE
sensitization
N= 301; n= 36 1.00 1235 15 7
FEV z-score N= 525 0.99 0 0 0
FVC z-score N= 525 0.95 0 0 0
FEV/FVC z-score N= 525 1.11 0 0 0
% Bronchodilator response N= 454 0.87 130 50 0
λ genomic inflation factor, EWAS epigenome-wide association analyses, FeNO fractional exhaled nitric oxide, FDR false discovery rate, DMRs differentially methylated regions with ≥5 CpGs with a
Stouffer FDR P < 0.05, IgE immunoglobulin E, FEV forced expiratory volume, FVC forced vital capacity, PCs principal components
aNumber of differentially methylated CpGs (FDR <0.05 and Bonferroni correction) and DMRs (≥5-CpGs and FDR < 0.05)
bAnalyses adjusted for child race/ethnicity, sex, age at sample collection, BMI z-score, maternal education, smokers living in the house, sine and cosine of season at sample collection, and cellular
heterogeneity (10 PCs from ReFACToR)
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specific IgE to environmental allergens and allergic asthma were
a subset of the sites associated with FeNO (>79%) (Supple-
mentary Table 2). The top 20 differentially methylated CpGs
ranked on significance associated with current asthma are
shown in Table 3. In addition, multiple DMRs with five or more
CpGs (EPX (eosinophil peroxidase), ACOT7, SORCS2 genes)
were overlapping across phenotypes like FeNO, allergic asthma,
environmental IgE sensitization, and total IgE (Tables 4 and 5).
BDR was the only trait with a unique nasal DNAm signature,
showing no overlap with any of the other phenotypes con-
sidered (Supplementary Table 2). Summary results and CpG
annotation for significant EWAS results are shown in the
supplementary material for Asthma (Supplementary Data 1),
FeNo (Supplementary Data 2), total IgE (Supplementary
Table 3), Environment IgE sensitization (Supplementary
Table 4), allergic asthma (Supplementary Data 3), and BDR
(Supplementary Data 4).
Functional gene categories represented in DMRs and indivi-
dual CpGs found for FeNO, asthma, and allergy were eosinophilic
activity (EPX, CLC, PRG2), and Th2 responses (IL-4, ZFPM1).
Differentially methylated CpGs and sites associated with FeNO
related to functions of solute transport and intracellular
membrane trafficking (SLC25A25, SLC39A4, DNAH17, VTI1A),
T cell activation (LAX), oxidative stress (VKORC1L1), and mucin
production (GALNT7). We also observed differential nasal
DNAm of asthma-associated genes identified in previous
independent genome‐wide association studies (GWAS): TNIP-
115, IL-1316, and CHI3L117 for FeNO DMRs (Supplementary
Data 5). Lower DNAm of the CHI3L1 gene responsible for
the production of the chitinase-like protein YKL-40, a mediator
associated with Th2 responses18, was differentially methylated for
a DMR relative to FeNO and for a CpG (cg19081101) for asthma
and allergic asthma. Greater DNAm of several CpGs annotated to
the PRTN3 gene was associated with higher FeNO and allergic
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Fig. 2 Nasal epigenome-wide associations for fractional exhaled nitric oxide (FeNO), asthma, and allergic asthma. Uncorrected −log10(P values) plotted in
the y-axis for each CpG site and sorted by chromosomal and genomic position on the x-axis. Adjustment for multiple testing was accounted for each
epigenome-wide association analyses by controlling the false discovery rate (FDR <0.05), horizontal orange dashed line, and Bonferroni threshold for
statistical significance (P < 6.95 × 10−8) shown in the solid red horizontal line. a Manhattan plot of epigenome-wide association analyses (EWAS) for
fractional exhaled nitric oxide (FeNO), b Manhattan plot of EWAS for current asthma, and c Manhattan plot of EWAS for current allergic asthma
Table 3 Top 20 differentially methylated CpGs associated with current asthma compared to never reporting asthma
CpG Chr % difference in DNAm Unadjusted P q value UCSC gene Other close gene Region
cg10555106 1 −3.20 3.19E− 07 0.019 LOC388588 SMIM1 Inside
cg04165922 1 5.24 1.05E− 07 0.013 NOS1AP NOS1AP Inside
cg05461268 2 6.09 7.45E− 07 0.024 DNER DNER Inside
cg10117579 2 3.57 8.85E− 08 0.013 COPS8 Upstream
cg24113459 3 −2.65 8.48E− 08 0.013 GLB1 GLB1 Inside
cg04217850 3 −1.82 4.89E− 07 0.022 SLC25A26 SLC25A26 Inside
cg13521315 3 2.43 5.52E−07 0.022 TMCC1 TMCC1 Inside
cg27187848 5 2.84 1.84E− 07 0.015 PCDHGA8 PCDHGA8 Inside
cg18321881 7 3.42 2.31E− 07 0.017 FKBP9 AVL9 Inside
cg18666454 7 −2.71 5.13E− 07 0.022 KCNH2 KCNH2 Inside
cg22060869 7 −1.95 1.29E− 07 0.013 KCNH2 KCNH2 Inside
cg16044211 9 0.48 3.42E− 07 0.019 FAM129B FAM129B Inside
cg11157850 14 −2.25 1.11E− 07 0.013 CHGA Upstream
cg16409452 14 −2.34 6.59E− 07 0.024 EVL EVL Inside
cg17148519 16 −1.26 5.18E−07 0.022 USP7 USP7 Inside
cg04010582 17 −1.51 3.21E− 07 0.019 RAB11FIP4 RAB11FIP4 Inside
cg04727951 17 −2.00 5.94E− 08 0.013 MSI2 MSI2 Inside
cg13000015 17 −2.07 4.14E− 07 0.021 CCDC57 CCDC57 Inside
cg17054995 19 −1.45 1.84E− 07 0.015 LGALS4 LGALS4 Promoter
cg24082440 21 −1.06 8.16E− 08 0.013 MRAP MRAP Inside
Chr chromosome, DNAm DNA methylation
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asthma. The PRTN3 protein has been previously shown to have
altered levels of abundance in the nasal epithelium of individuals
with current allergic rhinitis19.
In analyses of asthma and allergy, we observed lower DNAm
of several CpGs in genes regulating eosinophilic and Th2
responses: EPX and IL-4, respectively. Lower DNAm of PRG2,
which encodes for a pro-eosinophil major basic protein, was
associated with FeNO and allergic asthma. Lower DNAm of
CLC, a gene for lysophospholipase expressed in eosinophils,
was associated with current asthma, allergic asthma, and FeNO.
The ZFPM1 gene known to facilitate Th1 differentiation
through the downregulation of the Th2 cytokine IL-420 had
lower DNAm levels for participants with higher levels of FeNO
(DMR), total IgE, environment IgE sensitization, asthma, and
allergic asthma.
Solute carriers and intracellular transport genes were differen-
tially methylated. For example, the VTI1A gene, part of the
SNARE protein family associated with membrane transport and
permeability, had lower DNAm for one site (cg26724455) among
allergic asthmatics and was differentially methylated for several
sites relative to higher FeNO. Lower regional DNAm in genes for
solute carriers and intracellular transport (SLC25A25, DNAH17)
were associated with FeNO. In addition, a DMR in the ADAM-8
gene, a metalloprotease involved in cell matrix interactions, was
hypomethylated for FeNO (Supplementary Data 5). Another
DMR associated with FeNO and environment IgE sensitization
was found within SBNO221, a downstream mediator of anti-
inflammatory IL-10 responses. Hypomethylation of a gap
junction protein gene (GJA4) was observed for sensitization to
environmental allergens (Supplementary Table 4).
Table 4 Top 20 DMRs associated with log10 FeNO measurements
Chromosome: Position Width (bp) Number of CpGs Stouffer P Mean % difference in DNAm UCSC gene
Chr17:56,269,170–56,270,828 1659 8 6.85E− 40 −3.08 EPX
Chr11:44,091,987–44,092,987 1001 5 9.28E− 26 −2.18 ACCS
Chr1:6,340,110–6,342,888 2779 9 2.57E− 21 −2.84 ACOT7
Chr19:847,943–848,896 954 5 4.09E− 19 2.92 PRTN3
Chr17:62,307,787–62,309,293 1507 7 2.02E− 18 −1.88 TEX2
Chr1:203,155,884–203,156,784 901 6 7.31E− 18 2.51 CHI3L1
Chr10:114,437,411–114,438,072 662 5 1.35E− 17 −1.71 VTI1A
Chr16:88,539,861–88,540,992 1132 7 2.90E− 16 −2.52 ZFPM1
Chr16:357,249–358,591 1343 7 4.78E− 15 −1.63 AXIN1
Chr1:27,240,319–27,241,913 1595 11 1.31E− 14 −2.12 NR0B2
Chr17:81,039,326–81,043,782 4457 17 2.67E− 13 −2.02 METRNL
Chr11:64,642,144–64,643,272 1129 7 3.01E− 12 −1.29 EHD1
Chr17:72,442,179–72,443,401 1223 6 3.38E− 12 3.14 GPRC5C
Chr20:35,503,983–35,504,553 571 8 1.20E− 11 −2.26 TLDC2
Chr4:7,637,289–7,638,050 762 5 5.54E− 11 2.43 SORCS2
Chr20:4,764,077–4,764,312 236 5 5.57E− 11 −1.19 RASSF2
Chr17:76,564,134–76,565,673 1540 8 8.00E− 11 −1.66 DNAH17
Chr8:141,046,436–141,047,408 973 6 1.10E− 10 −1.85 TRAPPC9
Chr5:132,008,525–132,009,947 1423 7 2.71E− 10 −1.73 IL4
Chr9:130,859,191–130,860,839 1649 11 1.11E− 09 −1.21 SLC25A25
DMRs differentially methylated regions, FeNO fractional exhaled nitric oxide, DNAm DNA methylation
Table 5 DMRs associated with log10 total IgE, environment IgE sensitization, and allergic asthma
Chromosome: Position DMRs for total IgE
Width (bp) Number of CpGs Stouffer P Mean % difference
in DNAm
UCSC gene
Chr17:56,269,170–56,270,249 1080 7 0.019 −1.01 EPX
Chr4:7,637,289–7,638,050 762 5 0.025 0.95 SORCS2
Chr6:41,130,718–41,131,213 496 5 0.029 0.85 TREM2
DMRs for environment IgE
sensitization
Chr4:7,637,289–7,638,050 762 5 0.006 1.32 SORCS2
Chr11:73,115,417–73,116,329 913 5 0.010 1.07 FAM168A
Chr19:1,154,276–1,155,738 1463 6 0.019 1.07 SBNO2
Chr1:6,340,443–6,342,159 1717 6 0.027 −1.31 ACOT7
DMRs for allergic asthma
Chr17:56,269,170–56,270,828 1659 8 1.82E− 04 −2.87 EPX
Chr1:87,596,049–87,597,369 1321 5 4.12E− 04 −2.59 LINC01140
Chr20:4,764,077–4,764,312 236 5 9.54E− 04 −1.58 RASSF2
Chr6:29,592,854–29,593,913 1060 5 0.027 3.10 GABBR1
Chr1:6,645,094–66,45,463 370 5 0.030 −2.60 ZBTB48
Chr9:116,326,652–116,327,278 627 6 0.033 3.67 RGS3
Chr9:101,705,161–101,705,792 632 5 0.033 −1.58 COL15A1
DMRs differentially methylated regions, IgE immunoglobulin E, DNAm DNA methylation
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Among differentially methylated genes, we also looked at
biological pathways enriched in the Reactome database. The top
differentially methylated Reactome pathway was observed for
neutrophil degranulation followed by signaling by interleukin
pathways for allergic asthma and FeNO. Genes found for
asthmatics were enriched in the interleukin-2 family signaling
as well as the SUMOylation of intracellular receptor pathways
(Fig. 3).
Previous findings of asthma and blood DNAm. In addition to
identifying differentially methylated CpGs and DMRs from our
nasal samples, we checked individual CpGs found in whole blood
to be associated with asthma in children from a large meta-
analysis5. This meta-analysis identified 14 differentially methy-
lated CpGs in leukocytes from children with asthma compared to
non-asthmatics using data from six European cohorts (age 4–16
years). In our nasal DNAm data, 13 sites were differentially
methylated and consistent in direction. We were unable to test
one of the CpGs (cg11456013; AMD1) as it is unique to the
Infinium Human Methylation 450K (Supplementary Table 5).
One of the previously reported CpGs (cg13835688) in this meta-
analysis was annotated to the SLC25A25 gene. In our agnostic
regional analyses, we observed an entire DMR with lower DNAm
covering 11 CpGs for the SLC25A25 gene associated with
higher FeNO.
Replication in nasal epithelial cells. We tested for replication of
our top differentially methylated findings of asthma and allergic
asthma in an external cohort with nasal epithelial cells collected
from the posterior portion of the inferior turbinate and analyzed
with the Infinium Human Methylation 450K BeadChip6. We
checked for replication of the 285 differentially methylated CpGs
for asthmatics of which 95 probes were found in the 450K.
Among the 95 CpGs found to be differentially methylated for
asthmatics in our study and present in the 450K, 58 CpGs
replicated (61%) after controlling for multiple comparisons (FDR
< 0.05 for 95 comparisons) in the replication cohort with con-
sistent direction and magnitude of association for all 58 CpGs
(Supplementary Data 6). Replicated CpGs included several sites
annotated to the ACOT7, EPX, and EVL genes. For allergic
asthma analyses, there were 375 CpG probes present in the Yang
et al. 450K dataset of which 199 CpGs (53%) replicated with an
FDR < 0.05 and 197 of these had consistent direction of asso-
ciation (Supplementary Data 7). Replicated CpGs included sev-
eral sites annotated to the ACOT7, ZFPM1, PRG2, EPX, and
EVL genes.
We also compared our results to data from EVA-PR, a
case–control study of asthma in Puerto Rican children and
adolescents, which measured the nasal methylome using nasal
epithelial cells collected from the inferior turbinate22. In this
external cohort’s findings for atopic asthma, we identified 61%
(48/79) of CpGs that replicated (FDR < 0.05 for 48 comparisons),
all with consistent direction of association including multiple
CpGs annotated to EVL and EPX genes for our asthma results
(Supplementary Data 6). For our allergic asthma results, 59%
(187/315) of CpGs replicated (FDR < 0.05 for 187 comparisons),
but two associations had opposite directions of effect (Supple-
mentary Data 7). Lastly, for environment IgE sensitization four
out seven CpGs replicated (GJA4, ACOX2, PRKAG2, CYP27B1/
METTL1) and all seven associations had consistent directions
of effect (Supplemental Table 6). Notably, in the EVA-PR study
analysis of atopy, two of our top CpGs were replicated among the
top 30 differentially methylated findings from sorted CD326+
epithelial cells (cg15006973; GJA4 and cg20372759; CYP27B1/
METTL1 genes). In this cohort, they were able to test for DNAm
and gene expression relationships, and several of our top
differentially methylated CpGs were shown to be associated
with expression. Namely, for environment IgE sensitization
(METTL1), for allergic asthma (NTRK1), and several for FeNO
(MAP3K14, NTRK1, FBXL7, PCSK6, SLC9A3, CDH26, CAPN14,
and MAP3K14).
Epigenetic clock: epigenetic age acceleration. We evaluated
epigenetic age acceleration estimated using the nasal methylome.
The correlation between chronological age and DNAm-Age was
moderate (r= 0.19, P < 0.0001, Supplementary Fig. 2). We
observed significant epigenetic age acceleration in children with
current asthma (0.74 years; 95% confidence interval (CI): 0.02,
1.46) and even greater age acceleration for children with allergic
asthma (1.30 years; 95% CI: 0.36, 2.23). For every 10-fold increase
in FeNO, we observed that epigenetic age was accelerated by 1.11
years (95% CI: 0.39, 1.83). Similarly, every 10-fold increase in
Extracellular matrix organization
Oncogenic MAPK signaling
SUMOylation of intracellular receptors
Interleukin-2 family signaling
Signaling by receptor tyrosine kinases
Signalling to RAS
Interleukin receptor SHC signaling
Interleukin-4 and interleukin-13 signaling
Signaling by interleukins
Neutrophil degranulation
Allergic asthma
(575)
Asthma
(137)
FeNO
(2633)
Gene ratio
0.025
0.050
0.075
0.15
0.10
0.05
p.adjust
Fig. 3 Differentially methylated gene ontology categories. Gene enrichment analyses for gene ontologies present in the Reactome database that
were differentially methylated in epigenome-wide association analyses (false discovery rate (FDR) < 0.05) for allergic asthma, asthma, and fractional
exhaled nitric oxide (FeNO)
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total IgE was associated with epigenetic age acceleration of 0.58
years (95% CI: 0.15, 1.01). Participants with environmental IgE
sensitization had on average 0.83 years of epigenetic age accel-
eration (95% CI: 0.27, 1.39) (Table 6).
Discussion
We report epigenome-wide associations for nasal samples among
several traits related to asthma, allergy, and lung function. For
current asthma and elevated biomarkers of allergic disease (FeNO
and IgE), we observed multiple DMRs of genes that may alter the
structure and function of epithelial cells, including those encoding
for solute carriers and membrane transport proteins, oxidative
stress response and mucin production enzymes. We observed a
strong, consistent signal for lower DNAm of genes driving Th2
and eosinophilic responses, with EPX as the top DMR across
asthma and allergy phenotypes. We did not observe associations
between nasal DNAm and lung function or allergic rhinitis.
Finally, we show that epigenetic age of nasal samples is acceler-
ated by asthma and is correlated with elevated biomarkers of
allergic disease.
Comparison of our nasal methylome findings to a meta-
analysis of asthma in circulating leukocytes5 from children yiel-
ded consistent results. Asthma associated CpG sites tested in
whole blood were also differentially methylated in our sample of
nasal cells. This consistency suggests that the methylome sig-
nature in asthma is stable in whole blood, nasal cells, and
potentially other tissues. We observed consistent lower nasal
DNAm in asthmatics at the CpGs identified and even greater
effect sizes when compared to meta-analysis results from whole
blood. In the meta-analysis, the authors also reported on effect
sizes from isolated eosinophils of asthmatic vs. non-asthmatics
and observed consistent and even stronger associations (>10%
DNAm differences) in this target cell type. While our associations
are consistent and stronger in magnitude compared to whole
blood results, they are weaker (<6% DNAm differences) when
compared to the isolated eosinophil results, suggesting that the
strength of these epigenetic signatures may vary by target tissue.
Eosinophils are present in normal mucosa, but their abundance is
greater in the late phase of atopic reaction23. While differences in
DNAm in whole blood from the EWAS meta-analysis were
replicated in isolated eosinophils, none of the differentially
methylated genes were directly associated with eosinophil func-
tion. In contrast, our nasal methylome DMR findings identified
lower DNAm of the EPX for FeNO, total IgE, and allergic asthma.
In addition to comparing our results to EWAS in whole blood, we
replicated our findings in two independent case–control studies
that used the Illumina 450K and sampled nasal epithelial cells
from the inferior turbinate6. While we were not able to test for
replication of all sites due to probe density differences across
arrays and preprocessing, we did replicate >50% of the findings
from CpGs available in the two cohorts with consistent magni-
tude of effects, including multiple CpGs annotated to ACOT7,
ZFPM1, PRG2, EPX, GJA4 CYP27B1/METTL1, and EVL genes.
Lastly, we observed differential DNAm of genomic regions of
three genes previously associated with asthma or biomarkers of
asthma in GWAS, TNIP-115, IL-1316, and CHI3L117. These
findings illustrate the relevance of nasal anterior nares cells for
epigenetic studies of asthma. Two of these genes, IL-13 and
CHI3L1, show high expression of their protein products in the
lungs of asthmatics, and both are known to regulate Th2
response24,25. In contrast, none of the DNAm sites reported in
the blood leukocyte EWAS meta-analyses were within known
asthma GWAS hits5. Lower regional DNAm of the ADAM-8
gene, an airway remodeling metalloprotease acting downstream26
of the asthma GWAS gene ORMDL316,27,28, was observed for
FeNO in our data. These results indicate that the nasal cellular
compartment may be more sensitive to asthma-associated DNAm
differences compared to whole blood, and potentially an optimal
tissue for detecting epigenetic modifications of known biologically
relevant.
We observed minimal overlap of our nasal DNAm findings
with cord blood DNAm patterns prospectively linked to devel-
opment of childhood asthma and allergy. For example, higher
DNAm of SMAD3 in infant’s cord blood DNA has been asso-
ciated with asthma risk in three independent cohort studies,
particularly in children with a maternal history of asthma29. This
modulator of tumor growth factor-β (TGF-β) signaling, with
downstream implications for differentiation of T-regulatory cells
and Th17 cells30, was not differentially methylated in our ana-
lysis. However, hypermethylation of TGFB1 itself was observed in
our nasal methylome analysis for allergic asthma and FeNO,
suggesting that TGF-β signaling is altered in current disease or
with concomitant elevated allergic disease biomarkers.
In Project Viva, our own prior analysis of cord blood DNAm
identified several associations with mid-childhood (7.8 years) IgE
levels8. These longitudinal associations were not re-capitulated in
the current cross-sectional analysis. In contrast to the cord blood
analyses, many of the genes cross-sectionally associated with IgE
in whole blood analyses from mid-childhood (ACOT7, ZFPM1,
IL4, IL5RA, EPX, and PRG2)8 consistently had lower nasal
DNAm among DMRs found for FeNO, total IgE (EPX), envir-
onment IgE (ACOT7), and allergic asthma (EPX). Epigenetic
signatures present at birth with an influence on physiological
trajectories may not persist, so that later assessments of
epigenome-wide differences by current disease status may differ
from the transient epigenetic modifications or might vary by
tissue. Our previous analyses of prenatal environmental expo-
sures in cord blood and subsequent child blood suggest that
DNAm associations might be malleable and non-persistent as
children develop31,32.
One previous study from the Inner City Asthma Consortium
interrogated peripheral blood mononuclear cells (PBMCs) from
asthmatic children compared to controls. In this study comparing
97 childhood asthma cases and 97 controls, Yang et al.33 reported
differential PBMC DNAm of genes involved in T cell maturation
(RUNX3), Th2 immunity (IL-4), and oxidative stress (catalase).
Some of their gene-specific findings overlap with specific DNAm
marks in our data for asthma: FeNO and environment IgE sen-
sitization (lower DNAm of IL-4, ACOT7, ZFPM1), or FeNO and
allergic asthma (RUNX3); whereas other findings revealed
Table 6 Association of epigenetic age acceleration with
asthma, allergy, and lung function
Predictor Epigenetic age
accelerationa (95% CI)
P value
Current asthma 0.74 (0.02, 1.46) 0.04
FeNO (ppb) 1.11 (0.39, 1.83) 0.003
Current allergic rhinitis 0.61 (−0.25, 1.46) 0.16
Total IgE (kU L−1) 0.58 (0.15, 1.01) 0.009
Environment specific IgE
sensitization
0.83 (0.27, 1.39) 0.004
Current asthma with
environment IgE sensitization
1.30 (0.36, 2.23) 0.007
FEV z-score −0.13 (−0.36, 0.09) 0.24
FVC z-score −0.09 (−0.32, 0.15) 0.47
FEV/FVC z-score −0.11 (−0.35, 0.13) 0.35
% Bronchodilator response 0.01 (−0.03, 0.05) 0.59
FeNO fractional exhaled nitric oxide, CI confidence interval, IgE immunoglobulin E, FEV forced
expiratory volume, FVC forced vital capacity, DNAm DNA methylation
aResiduals (ɛi) of DNAm-Age ~chronological age+ ɛi
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different DNAm marks, although the functions of the differen-
tially methylated genes were similar to those reported in our
findings (oxidative stress, T cell differentiation). An additional
nasal epigenome wide study in the Inner City Asthma Con-
sortium compared DNAm and gene expression of the nasal
epithelium in 36 atopic asthmatic subjects and 36 controls6.
Interestingly, top DMRs were not in Th2 pathway genes, but
instead identified altered DNAm signatures for genes associated
with epithelial cell migration, components of the extracellular
matrix, cell adhesion, epigenetic regulation, and airway obstruc-
tion. These two studies differ from our own in that both con-
tained smaller sample sizes, participants were from different
racial and SES backgrounds, used the older array (450K), and
neither study included a nasal EWAS of allergic disease bio-
marker levels such as FeNO, which in our data showed the
greatest number of associations. However, we were able to
replicate over 50% our findings in samples of nasal epithelial cells
observed to be differentially methylated for asthma, allergic
asthma, and IgE sensitization found in the 450K data from two
previous studies with different methodologies.
In our EWAS of asthma and related phenotypes, we chose to
sample from the anterior nares, as it provides a good proxy of
DNAm states in the airway34, arguably the most relevant target
tissue for asthma and allergic airway inflammation. We sampled
from the anterior nares, a nasal region shown to have similar
within-subject DNAm profiles as compared to cells from the
inferior turbinate. Sampling from the anterior nares does not
require a speculum, and subjects report less discomfort with this
technique as compared to inferior turbinate sampling, making it
more amenable for use in pediatric populations35. While we did
not count cell populations in our nasal swab samples, prior work
on the cell distributions of samples from the anterior nares of
healthy adult subjects showed, on average, 65% respiratory epi-
thelial cells, approximately 34% squamous cells, and ≤1% of
inflammatory cells35. Therefore, differences in DNAm by asthma
or allergic disease phenotypes can arise from any of these cell
types. Indeed, differential DNAm of genes associated with
respiratory epithelial barrier integrity as well as immune response
were observed in our results. To determine whether our DNAm
signatures may simply reflect differences in cell type composition
by phenotype, we performed reference-free cell-type adjustment
using ReFACTor, a method shown to perform well when
benchmarked to reference-based methods36. Signals were mark-
edly reduced for asthma, IgE, and environment-specific IgE,
suggesting that a large proportion of the variability might be
driven by differences in cell types. However, multiple DMRs
remained for FeNO, suggesting that some of the DNAm bio-
markers are independent of cell-type differences, such as DMRs
in EPX and EVL genes that replicated in two other cohorts.
In addition to identifying disease biomarkers, DNAm also
serves as a marker of biological aging. For example, the epigenetic
clock has been linked to greater risk of diseases and mortality37,38.
Our own cohort has reported associations between epigenetic age,
estimated in blood, in relationship to asthma, allergy, or lung
function39. Consistent with this previous finding from blood, we
also observed epigenetic age acceleration by asthma and allergy
using nasal samples. Not surprisingly, the correlation between
chronological age and DNAm-Age was moderate (r= 0.19) given
the small SD in chronological age for our sample (SD= 0.65
years)40. Yet, our results show that nasal samples are a viable
tissue to capture epigenetic age acceleration correlated with
asthma and allergy.
Our analysis of the nasal methylome in asthma and its related
phenotypes has several strengths, namely the size of the study
(over 500 subjects), the use of multiple phenotypes related to
allergic disease, including asthma, biomarkers of allergy, and
airway inflammation, assessment of over 700,000 CpG sites, and
over 50% replication rate in two independent cohorts. Some
weaknesses and caveats also deserve mention. We were not able
to directly assess cell-type composition. We did however adjust
bioinformatically for cell-type heterogeneity. Additionally, while
it was our intention to measure gene expression, we were unable
to collect sufficient high-quality RNA from the anterior nares or
enough concentration (250–300 ng μL−1).
We observed widespread nasal DNAm variability associated
with asthma, allergic asthma, FeNO, total IgE, environment IgE,
and to a lesser extent BDR. Significant DNAm variability inclu-
ded known asthma-associated genes, genes involved in Th2 and
eosinophilic responses, and genes that may alter permeability and
function of the respiratory epithelium. We validated previous
results from blood EWAS for asthma and replicated findings in
two independent cohorts with nasal epithelial cells. The DNAm
signatures might indeed reflect the cellular milieu serving as a
sensitive biomarker of airway disease. Further assessment of this
DNAm variability will contribute to asthma endotyping and may
help elucidate epigenomic targets for interventions, monitoring
and progression to improve the course of airway diseases. Finally,
we show that epigenetic age is accelerated with elevated bio-
markers of allergy and asthma. Taken together, our findings
indicate that the nasal cellular epigenome serves as a sensitive
epigenetic biomarker of asthma, allergy, and airway responsive-
ness, as well as the compartment specific biologic processes
underlie these phenotypes.
Methods
Study population. Children were participants in Project Viva, a prospective pre-
birth cohort study recruited between 1999 and 2002 during the mothers’ first
prenatal visits at Atrius Harvard Vanguard Medical Associates, a multispecialty
medical group practice in Massachusetts, United States41. Eligibility criteria
included fluency in English, gestational age <22 weeks at the first prenatal visit, and
singleton pregnancy. Of the total 2128 live births, 547 children were re-contacted
during an early-teen in-person visit (mean 12.9 years) and provided consent for
nasal swab sample collection. Mothers provided written informed consent at
recruitment and at postpartum follow-up visits. The Institutional Review Board of
Harvard Pilgrim Health Care reviewed and approved all study protocols. Nasal cell
DNA collection, fraction exhaled nitric oxide, BDR, allergen sensitization, and the
current asthma outcome were all assessed at the same time-point during nasal
sample collection.
DNAm measurements. Trained research assistants collected nasal swabs from the
anterior nares, previously demonstrated to yield respiratory epithelial cells35. Nasal
swabs were immediately stored in lysis buffer and frozen until processing. DNA
was isolated using the Maxwell 16 Buccal Swab LEV DNA Purification Kit fol-
lowing the manufacturer’s instructions (Promega, Madison, WI, USA).
Epigenome-wide DNAm measurements were performed on DNA extracted
from nasal samples with the Infinium MethylationEPIC BeadChip (Illumina, San
Diego, CA, USA). The Infinium MethylationEPIC BeadChip quantifies DNAm in
over 850,000 CpGs at a single-nucleotide resolution for each sample. Samples were
randomly allocated to seven 96-well plates. Sample plates and chips were
randomized to ensure balance by sex, current asthma status, current allergic
rhinitis, and race to minimize potential confounding by batch effects.
DNAm data were imported into the R statistical software for preprocessing
using minfi42. We first performed quality control at the sample level, excluding
samples with overall low intensities, which indicates low-quality (intensities < 10.5;
n= 3), samples that mismatched on recorded sex (n= 4) and samples with mixed
genotype distributions on the measured SNP probes (59 SNP probes), indicating
possible sample contamination (n= 8). In addition, we excluded technical
duplicates (n= 35). A total of 547 high-quality samples were retained for analyses.
We performed quality control at the probe level by computing a detection
P value relative to control probes. Namely, we excluded 4161 probes with non-
significant detection (P > 0.05) for 5% or more of the samples. We also excluded
18,978 probes annotated to sex chromosomes, 2835 non-CpG probes, 5516 probes
with SNPs at the single base extension (minor allele frequency (MAF) ≥ 5%),
70,737 probes containing an SNP (MAF ≥ 5%), and 5215 probes with an SNP at the
CpG site (MAF ≥ 5%). Finally, we excluded 40,377 cross-reactive probes previously
identified in the MethylationEPIC BeadChip43. Subsequently, a total of 719,075
high-quality probes were included in all analyses (Supplementary Table 7). We
preprocessed our data using functional normalization with three PCs from the
control probes to adjust for technical variability44. To adjust for probe-type bias
(I vs. II), we used the regression on correlated probes method that leverages
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genomic proximity to adjust the distribution of type 2 probes45. Lastly, we used
ComBat from the sva package to adjust for sample plate (seven 96-well plates) as a
technical batch variable46. We visualized the data using density distributions at all
processing steps and performed PC analyses to examine the associations of
methylation differences with technical, biological, and measured traits with global
DNAm variation using ENmix47, and PCA plots for technical duplicate agreement.
Fractional exhaled nitric oxide. NO is a mediator involved in chronic inflam-
matory diseases and Th2-mediated immune responses.48 Measurement of NO in
exhaled air, as FeNO, is a non-invasive biomarker of airway inflammation that
correlates with airway eosinophilia.49 We measured FeNO levels with a portable
electrochemical device (NIOX MINO; Aerocrine AB, Stockholm, Sweden), which is
in agreement with published procedures for FeNO measurement.50 Prior to
measurement of FeNO, we asked participants to breath in through an NO
scrubbing filter and then exhale out into the room air two times. We then
instructed participants to inhale through the scrubbing filter and exhale into the
FeNO analyzer at a flow rate of 50 mL s−1. Following American Thoracic Society
guidelines, to ensure measurement of lower, not upper, airway FeNO, we did not
use nose clips and we quantified the last 3 s of the exhalation.50 We performed this
procedure twice. The mean of these two measurements was used in all subsequent
analyses.
Current asthma and allergic rhinitis. Current asthma was defined as mother’s
report of a doctor’s diagnosis of asthma since birth reported on the early teen
questionnaire plus report of wheeze or asthma medication in the past year at early
teen follow-up (comparison group had no asthma diagnosis, no wheeze, or no
asthma medication use). Current allergic rhinitis was defined as mother’s report of
a doctor’s diagnosis of hay fever since birth reported on the early teen ques-
tionnaire plus report of sneezing, runny nose, or blocked nose without cold or flu
in the past year and current symptoms (moderate-level nasal congestion/stuffiness,
nasal blockage, or trouble breathing through the nose in the past month) at the
time of nasal swab collection (comparison group had no hay fever diagnosis, no
current nasal symptoms at swab collection and no sneezing, runny nose or blocked
nose symptoms without cold or flu in the past year).
IgE and sensitization to environmental allergens. We measured total IgE by
using the ImmunoCAP assay (Phadia, Uppsala, Sweden). Sensitization to envir-
onmental allergens was defined as any specific IgE level > 0.35 IUmL−1 to com-
mon indoor allergens (Dermatophagoides farinae, cat and dog dander), mold
allergens (Alternaria or Aspergillus species), or outdoor allergens (rye grass, rag-
weed, oak, and silver birch).
Lung function and bronchodilator response. Trained research assistants mea-
sured child height, weight, and lung function.41 We measured pre-bronchodilator
forced expiratory volume in 1 sFEV1 and FVC using the EasyOne Spirometer
(NDD Medical Technologies, Andover, MA, USA). We then administered two
puffs (90 μg per puff) of albuterol to each participant, and obtained post-
bronchodilator spirometry measures at least 15 min after the administration of
albuterol. We used the American Thoracic Society criteria for acceptability and
reproducibility, with the goal of coaching each subject to produce at least three
acceptable and at least two reproducible spirograms. We defined the BDR as a
percent change in absolute FEV1 after albuterol administration (postbronchodilator
FEV1 – prebronchodilator FEV1/prebronchodilator FEV1 × 100).
Statistical analyses. Among 547 participants with high-quality DNAm data eli-
gible for analyses, we report our sample’s demographic and biological character-
istics using means, standard deviations, or proportions. We performed EWAS
CpG-by-CpG by fitting linear regression models using limma with moderate test
statistics using an empirical Bayes estimation51. In EWAS models, we adjusted for
variables selected a priori and based on PCA plots: child race/ethnicity, sex, age at
sample collection in days, age- and sex-specific BMI z-score using US National
Reference Data, smokers currently living in the house, sine and cosine of season of
sample collection, maternal education in pregnancy, and cell-type heterogeneity.
We performed 10 independent EWAS to analyze nasal DNAm in relation to: (1)
current asthma vs. never, (2) current allergic asthma vs. never, (3) FeNO, (4) total
serum IgE levels, (5) any environment-specific IgE, (6) FEV z-score, (7) FVC
z-score, (8) FEV/FVC z-score, (9) BDR, and (10) current allergic rhinitis vs. never.
We bioinformatically controlled for cell-type composition using ReFACTor, a
reference-free method to adjust for cell-type composition in genome-wide DNAm
studies from heterogenous tissues52. We chose ReFACTor as it has been shown to
control the false-positive rate even when compared to reference-based methods36.
We adjusted for the first 10 PCs from ReFACTor (Supplementary Figure 3) as
proxy for nasal cellular heterogeneity. CpG-by-CpG EWAS results were adjusted
for multiple comparisons using a Bonferroni correction (P < 6.95 × 10−8).
Quantile–quantile plots for the regression P values were used to visually inspect
genomic inflation and we report the genomic inflation factor (λ) for unadjusted
and cell-type-adjusted analyses. We performed regional DNAm analyses using
DMRcate53 to identify DMRs associated with each trait. We defined a significant
DMR as a DNAm region ≥5 CpGs and evaluated statistical significance using a
Stouffer FDR-adjusted P <0.05. We evaluated the overlap among differentially
methylated CpGs for each EWAS surviving multiple testing adjustment.
Lastly, we estimated DNAm-Age using the Horvath multi-tissue epigenetic age
predictor40. We used epigenetic age acceleration from the residuals of a linear
model regressing DNAm-Age on chronological age as reported in the Horvath’s
online calculator: (https://dnamage.genetics.ucla.edu/). All statistical tests were two
sided and analyses were carried out using R, version 3.5.0 (www.r-project.org/).
Replication in epithelial nasal cells. We sought to replicate our top differentially
methylated findings of asthma and allergic asthma in an external cohort with nasal
epithelial cells collected from the posterior portion of the inferior turbinate from
the Inner City Asthma Consortium6. Briefly, in this study samples of nasal epi-
thelial cells from 36 atopic asthmatics and 36 controls with at least 80% ciliated
epithelial cells were collected and DNAm was measured using Illumina’s Infinium
Human Methylation 450K BeadChip. We downloaded publicly available data from
the Gene Expression Omnibus repository (GSE65163)6. To allow for direct com-
parability, we carried out the same pre-processing and analytical strategy used in
our study, including adjusting for cell type using ReFACTor (9 PCs). Among
differentially methylated CpGs found for asthma and allergic asthma, we compared
differences in DNAm in adjusted models and controlling the FDR <0.05.
We further tested for replication using a second independent study from The
Epigenetic Variation and Childhood Asthma in Puerto Ricans (EVA-PR), a
case–control study of childhood asthma in Puerto Rico22. Briefly, in this study,
nasal epithelial samples from 483 participants aged 9–20 years were collected, and
DNAm was measured using the Illumina’s Infinium Human Methylation 450K
BeadChip. Atopy was defined as at least one positive IgE to five common
aeroallergens in Puerto Rico; asthma was defined as physician’s diagnosis plus at
least one episode of wheezing in the previous year. We used data from the EVA-PR
EWAS for atopic asthma (vs. non-atopic controls) as replication for our analyses
on asthma and atopic asthma, and the EVA-PR EWAS for atopy as replication for
our analysis of IgE sensitization. We adjusted the FDR <0.05 among CpGs found in
both analyses.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Datasets generated and analyzed during the current study are not publicly available
because we did not obtain consent for such public release of epigenetic data from
participants. However, raw data to generate figures and tables are available from the
corresponding author with the appropriate permission from the Project Viva study team
and investigators (project_viva@hphc.org) upon reasonable request and institutional
review board approval. Summary statistics for all EWAS performed are available via
https://doi.org/10.6084/m9.figshare.8285612.v1.
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